Cargando…
Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients
Risankizumab is a humanized immunoglobulin (Ig) G1 monoclonal antibody developed and approved for the treatment of moderate-to-severe plaque psoriasis at a dose of 150 mg administered subcutaneously at weeks 0 and 4, and every 12 weeks thereafter. Ongoing trials are investigating the use of risankiz...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051925/ https://www.ncbi.nlm.nih.gov/pubmed/31758502 http://dx.doi.org/10.1007/s40262-019-00842-5 |